In contrast, the intravenous and subcutaneous applications of the anti-Nogo therapy failed to enhance the stroke-impaired grasping function compared to the control IgG, PBS, or untreated groups (Fig. 1B), although the applied anti-Nogo dosage was 10 times (for i.v.)and 15 times (for s.c.)higher than in the intrathecal condition. The gene discussed is RTN4; the disease is stroke disorder.